Hadassah

Hadassah Researchers Develop Definitive Biomarker for Cardiac Muscle Death and Link it to Death from Sepsis

Thursday, Jun 7 2018

Hadassah Medical Organization researchers, in collaboration with colleagues at the Hadassah-Hebrew University School of Medicine, have developed a blood test which definitively detects death of cardiac muscle cells following an acute heart attack and in the case of sepsis.

The new blood test uses methylation patterns within cell-free DNA circulating in the patient’s blood stream (cfDNA) to determine the extent of heart damage. Therefore, the researchers propose that cardiac cfDNA measurements can become a new specific marker for myocardial damage, potentially complementing currently available markers.

The plasma of healthy individuals contains essentially no cfDNA, whereas patients who have experienced an acute heart attack show a robust cardiac cfDNA signal that correlates with levels of troponin.Most interestingly, it was found that the presence of cardiac DNA in the plasma of patients with sepsis predicts a four times higher chance of these patients dying within 90 days of hospitalization. These findings, the authors say, indicate that myocardial cell death is an important determinant of mortality following sepsis, and that elevated cardiac cfDNA is a strong prognostic biomarker in sepsis. By the same token, the authors note, “the strong correlation between cardiac cfDNA and mortality underscores the importance of cardiac health in facilitating survival from sepsis. These findings may have implications for the management of septic patients.”

Although troponin, a protein biomarker, is the gold standard for diagnosing cardiac muscle damage, it does have limitations. As the researchers explain, it is difficult to determine if release of troponin into the bloodstream necessarily reflects death of cardiac muscle or just reversible cardiac muscle injury. In addition, renal dysfunction, a common condition in patients with heart disease, slows down clearance of troponin and complicates the interpretation of elevated troponin. In contrast, cardiac cfDNA directly reflects cardiac damage and is not altered by kidney dysfunction.

The researchers acknowledge that additional experiments are needed to test the idea that cardiac cfDNA is an exclusive marker of cardiomyocyte death, and to validate the clinical utility of this new biomarker.

The authors conclude that measurements of cardiac cfDNA capture cardiomyocyte (cardiac muscle) death associated with myocardial infarction, and that the cardiac cfDNA assay can identify myocardial cell death early after ischemia (insufficient blood flow) ensues. Additional more detailed clinical studies are required to determine how cardiac cfDNA compares to troponin in predicting infarct size and long-term cardiac function.

The study results were published in the April 24, 2018 online issue of Nature Communications in an article entitled “Non-invasive Detection of Human Cardiomyocyte Death Using Methylation Patterns of Circulating DNA.” The study was a collaboration among researchers from the Hadassah Medical Organization’s Department of Cardiology, Department of Cardiothoracic Surgery, Endocrinology and Metabolism Service, Department of Anesthesiology and Critical Care Medicine, and the Department of Developmental Biology and Cancer Research at The Institute for Medical Research Israel-Canada of the Hadassah-Hebrew University School of Medicine.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Aug 17 2018

Hadassah Mourns the Loss of Aretha Franklin and Urges Greater Awareness of Diagnosis and Treatment of Pancreatic Cancer

Sadly, the “queen of soul” Aretha Franklin passed away yesterday at age 76, due to an advanced pancreatic neuroendocrine tumor (pancreatic NET or PNET).

READ MORE ›
alt_text

Wednesday, Aug 15 2018

Hadassah Hospital’s Bone Marrow Transplant Department Receives International Acclaim

In a first for Israel, Hadassah Medical Organization’s Bone Marrow Transplantation and Cancer Immunotherapy Department has recently received full accreditation by the Joint Accreditation Committee ISCT-EUROPE & EBMT (JACIE), Europe’s only official accreditation body in the field.

READ MORE ›
alt_text

Tuesday, Aug 14 2018

Hadassah Hospital Helps Educate Mikvah Attendants To Bolster Women’s Health

After a woman emerges from the ritual bath (mikveh) and wraps herself in a towel, says mikveh attendant Daniella Salomon, “I keep an eye out” for anything unusual.

READ MORE ›
alt_text

Tuesday, Aug 7 2018

American Medical Attaché and Consulate Nurse Tour Hadassah Hospital Ein Kerem

Jennifer Kmiecinski, Medical Attaché to the Consulate General of the United States in Israel, visited Hadassah Hospital Ein Kerem earlier this month to assess the level of health care available to American personnel serving in Israel.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More